| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 12.2% | +32.2% | $184M | $43.4M | 4.22M | +30.9% | FMR LLC | Jul 31, 2025 |
| AI DMI LLC | 10.8% | $146M | 3.76M | AI DMI LLC | Feb 27, 2025 | |||
| ORBIMED ADVISORS LLC | 4.5% | $60.3M | 1.56M | ORBIMED ADVISORS LLC | Mar 10, 2025 | |||
| WELLINGTON MANAGEMENT GROUP LLP | 4.1% | -38.6% | $75.8M | -$48.3M | 1.43M | -38.9% | Wellington Management Group LLP | Jun 30, 2025 |
| Paradigm Biocapital Advisors LP | 3.5% | $46.9M | 1.21M | Paradigm BioCapital Advisors LP | Mar 31, 2025 | |||
| Atlas Venture Fund X, L.P. | 3.1% | $64.8M | 1.08M | Atlas Venture Fund X, L.P. | Aug 13, 2025 | |||
| Frazier Life Sciences Public Fund, L.P. | 3% | $61.3M | 1.03M | Frazier Life Sciences Public Fund, L.P. | Jun 30, 2025 | |||
| Bain Capital Life Sciences Opportunities III, LP | 3.3% | $38.1M | 984K | Bain Capital Life Sciences Opportunities III, LP | Dec 31, 2024 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Change | Price | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 10.7K | $708K | +$692K | $66.08 | 2 |
| 2025 Q2 | 34.1M | $1.8B | +$52.4M | $52.96 | 149 |
| 2025 Q1 | 33.2M | $1.65B | +$314M | $49.64 | 155 |
| 2024 Q4 | 26.6M | $1.68B | -$53.2M | $63.40 | 151 |
| 2024 Q3 | 27.3M | $1.34B | -$26.6M | $49.14 | 130 |
| 2024 Q2 | 27.6M | $1.24B | +$213M | $45.07 | 120 |
| 2024 Q1 | 22.2M | $1.38B | +$123M | $62.26 | 130 |
| 2023 Q4 | 7.88K | $455K | +$455K | $57.76 | 2 |
| 2023 Q3 | 19.9M | $934M | +$42.9M | $46.98 | 89 |
| 2023 Q2 | 19.1M | $849M | +$223M | $44.40 | 89 |
| 2023 Q1 | 14.6M | $310M | +$67.4M | $21.19 | 44 |
| 2022 Q4 | 10.8M | $215M | +$202M | $19.89 | 30 |